The Breakfast Grille BFM Media

It was announced that Sunzen Biotech will be exiting from its animal health business to focus on human health products and loan financing services. Executive chairman, Ching Chee Pun shares with us the rationale behind this decision, the outlook and why they appear to have a weak track record when it comes to M&A.
See omnystudio.com/listener for privacy information.

This Europe Day Michalis Rokas, Ambassador and Head of the EU delegation to Malaysia joins us to delve into topics such as Ukraine, Gaza, and the recently announced Free Trade Agreement (FTA) between Malaysia and the EU.
See omnystudio.com/listener for privacy information.

It has been increasingly more challenging to navigate the intersection between corporate responsibility and ethical footing. Alison Taylor, author of "Higher Ground: How Business Can Do the Right Thing in a Turbulent World" joins Philip See to share her insights on the topic and how businesses can help build trust.

Image Credit: Shutterstock.com
See omnystudio.com/listener for privacy information.

Multimedia Enhancement Operations (METEOR) was set up in 1998 as a consortium of Malaysia’s first 11 public universities, and is the parent company of Open University Malaysia. Does the METEOR Group business model provide a solution to the funding pressures faced by public universities? We discuss its performance record and expansion strategy with Group CEO Dato’ Naharudin Ali.
See omnystudio.com/listener for privacy information.

Singapore-based Golden Duck makes snacks and are most well-known for their salted egg yolk flavoured potato crisps and fish skin. They are up against some very staunch competition in their home country but has an advantage here with its link to Malaysia's Mamee-Double Decker. Golden Duck's co-founder and CEO Jonathan Shen shares what it has cost to get to where it is today and the challenges in marketing a snack that some might see as bougie.
See omnystudio.com/listener for privacy information.

The specialty chemical industry is expected to grow at a compounded annual growth rate of 5.2%, reaching USD316 billion by 2026. What opportunities are there in Asia for the world's leading company, Evonik? Questions we pose to Dr Claus Rettig, their President for APAC whilst asking what goes behind their decision to pick a country for expansion.
See omnystudio.com/listener for privacy information.